Participants 76 112 5
patients with chronic kidney disease
Participants 194 229 5
patients with mild renal impairment
Participants 386 449 6
patients who underwent percutaneous coronary intervention (PCI)
Participants 494 612 6
patients enrolled in the Enhanced Suppression of the Platelet IIb/IIIa Receptor with Integrilin Therapy (ESPRIT) trial
Participants 614 708 4
Patients were randomly assigned to placebo or eptifibatide as an adjunct to stent implantation
Participants 709 770 4
(1,755 with CrCl > or =60 ml/min and 289 with CrCl <60 ml/min
Participants 924 990 3
Patients with CrCl <60 ml/min were more likely to be older, women,
Participants 1645 1680 3
patients with mild renal impairment
